ENSC
HEALTHCAREEnsysce Biosciences Inc
$0.39-0.01 (-2.50%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ENSC Today?
No stock-specific AI insight has been generated for ENSC yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.31$2.75
$0.39
Fundamentals
Market Cap$4M
P/E Ratio—
EPS$-3.98
Dividend Yield—
Dividend / Share—
ROE-3.2%
Profit Margin-2.0%
Debt / Equity—
Trading
Volume106K
Avg Volume (10D)—
Shares Outstanding9.3M
ENSC News
20 articles- Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in AmsterdamYahoo Finance·May 8, 2026
- Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical StudyYahoo Finance·Apr 16, 2026
- Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain ProgramsYahoo Finance·Apr 7, 2026
- ENSC Making Great Strides Toward CommercializationYahoo Finance·Mar 31, 2026
- Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 30, 2026
- Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future PlansYahoo Finance·Mar 4, 2026
- Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) TechnologyYahoo Finance·Mar 3, 2026
- Update: Wall Street Set to Open Lower Friday as Investors Analyze Higher Than Expected Producer Prices; Oil Prices SurgeYahoo Finance·Feb 27, 2026
- BC-Most Active StocksYahoo Finance·Feb 27, 2026
- Wall Street Set to Open Lower Friday as Investors Analyze Higher Than Expected Producer Prices; Oil Prices SurgeYahoo Finance·Feb 27, 2026
- Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder ValueYahoo Finance·Feb 25, 2026
- Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry EventsYahoo Finance·Feb 23, 2026
- Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute PainYahoo Finance·Jan 28, 2026
- Ensysce Biosciences Expands Global Opioid Patent PortfolioYahoo Finance·Jan 21, 2026
- ENSC Expands its Global Patent PortfolioYahoo Finance·Jan 21, 2026
- Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose ProtectionYahoo Finance·Jan 8, 2026
- Ensysce Biosciences Issues Annual Shareholder LetterYahoo Finance·Jan 5, 2026
- Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)Yahoo Finance·Dec 12, 2025
- Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation OpioidYahoo Finance·Dec 9, 2025
- ENSC Enrolls First Patient in Critical Phase 3 TrialYahoo Finance·Dec 9, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$0.40
Day High$0.00
Day Low$0.00
52 Week High$2.75
52 Week Low$0.31
52-Week Range
$0.31$2.75
$0.39
Fundamentals
Market Cap$4M
P/E Ratio—
EPS$-3.98
Dividend Yield—
Dividend / Share—
ROE-3.2%
Profit Margin-2.0%
Debt / Equity—
Trading
Volume106K
Avg Volume (10D)—
Shares Outstanding9.3M
About Ensysce Biosciences Inc
Ensysce Biosciences, Inc., a clinical-stage biotechnology company, is dedicated to the development of various prescription drugs. The company is headquartered in La Jolla, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—